00:45 , Jan 12, 2017 |  BC Week In Review  |  Clinical News

Onapristone: Ph II halted

Arno said it halted enrollment in the Phase II portion of an open-label, U.K. Phase I/II trial evaluating twice-daily onapristone plus Zytiga abiraterone acetate after the company determined further enrollment was not justified based on...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Clinical News

Arno preclinical data

In human CF macrophages, Arno said AR-13 in combination with broad-spectrum antibiotics synergistically reduced antibiotic-resistant Burkholderia cenocepacia burden. In CF neutrophils, AR-13 alone significantly reduced Pseudomonas aeruginosa burden by 70%. Data were presented at the...
07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

AR-12 regulatory update

The European Commission granted Orphan Drug designation to AR-12 from Arno to treat cryptococcosis and tularemia. The small molecule 3-phosphoinositide dependent protein kinase-1 (PDPK1) inhibitor is in preclinical testing for the indications. It has completed...
08:00 , Jan 29, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: 3-phosphoinositide dependent protein kinase-1 (PDPK1); protein kinase B (AKT; AKT1; PKB; PKBA); ribosomal protein S6 kinase 70kDa polypeptide 1 (R

Cancer INDICATION: Cancer In vitro studies suggest that small molecule allosteric inhibitors of PDPK1 could enhance the anti-tumor activity of PDPK1 inhibitors to help treat cancer. The C-terminal domain of PDPK1 contains the PDPK1-interacting fragment...
07:00 , Sep 11, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Rett syndrome DNA (cytosine-5-)- methyltransferase 1 (DNMT1); 3-phosphoinositide dependent protein kinase-1 (PDPK1); aurora kinase A (AURKA; aurora-A); X inactive specific transcript (XIST); methyl CpG binding...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Biogen Idec, Sunesis, Takeda deal

Earlier this month, Sunesis in-licensed two preclinical cancer programs. Biogen Idec granted Sunesis exclusive, worldwide rights to develop and commercialize SNS-062 , a Bruton's tyrosine kinase (Btk) inhibitor in preclinical testing. Sunesis said that SNS-062...
07:00 , Oct 17, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Melanoma 3-Phosphoinositide-dependent protein kinase-1 (PDPK1); BRAF Studies in patient tumor samples and mice suggest PDPK1 inhibitors could help treat melanoma. In...
07:00 , Sep 19, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD); neurology 3-Phosphoinositide-dependent protein kinase-1 (PDPK1) Mouse and cell culture studies suggest inhibiting PDPK1 activity could help treat AD and prion-associated diseases. In...
07:00 , Sep 5, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer c-Myc (MYC); mammalian target of rapamycin (mTOR; FRAP; RAFT1); 3-phosphoinositide dependent protein kinase-1 (PDPK1); polo-like kinase 1 (PLK1; STPK13) Cell culture and mouse studies...
07:00 , Mar 21, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer K-Ras; 3-phosphoinositide-dependent protein kinase-1 (PDPK1) Mouse studies suggest inhibiting PDPK1 could help prevent mutant K-Ras-driven pancreatic ductal adenocarcinomas (PDACs)....